Discovery of β‑Arrestin-Biased 25CN-NBOH-Derived 5‑HT2A Receptor Agonists

The serotonin 2A receptor (5-HT2AR) is the mediator of the psychedelic effects of serotonergic psychedelics, which have shown promising results in clinical studies for several neuropsychiatric indications. The 5-HT2AR is able to signal through the Gαq and β-arrestin effector proteins, but it is curr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2022-09, Vol.65 (18), p.12031-12043
Hauptverfasser: Poulie, Christian B. M., Pottie, Eline, Simon, Icaro A., Harpsøe, Kasper, D’Andrea, Laura, Komarov, Igor V., Gloriam, David E., Jensen, Anders A., Stove, Christophe P., Kristensen, Jesper L.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 12043
container_issue 18
container_start_page 12031
container_title Journal of medicinal chemistry
container_volume 65
creator Poulie, Christian B. M.
Pottie, Eline
Simon, Icaro A.
Harpsøe, Kasper
D’Andrea, Laura
Komarov, Igor V.
Gloriam, David E.
Jensen, Anders A.
Stove, Christophe P.
Kristensen, Jesper L.
description The serotonin 2A receptor (5-HT2AR) is the mediator of the psychedelic effects of serotonergic psychedelics, which have shown promising results in clinical studies for several neuropsychiatric indications. The 5-HT2AR is able to signal through the Gαq and β-arrestin effector proteins, but it is currently not known how the different signaling pathways contribute to the therapeutic effects mediated by serotonergic psychedelics. In the present work, we have evaluated the subtype-selective 5-HT2AR agonist 25CN-NBOH and a series of close analogues for biased signaling at this receptor. These ligands were designed to evaluate the role of interactions with Ser1593×36. The lack of interaction between this hydroxyl moiety and Ser1593×36 resulted in detrimental effects on potency and efficacy in both βarr2 and miniGαq recruitment assays. Remarkably, Gαq-mediated signaling was considerably more affected. This led to the development of the first efficacious βarr2-biased 5-HT2AR agonists 4a–b and 6e–f, βarr2 preferring, relative to lysergic acid diethylamide (LSD).
doi_str_mv 10.1021/acs.jmedchem.2c00702
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9511481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2714391700</sourcerecordid><originalsourceid>FETCH-LOGICAL-a1291-7e4acf1d7893693aa031157474e5e5638ae59f0256bbfb4e9d7c19f4ce1c91463</originalsourceid><addsrcrecordid>eNpVkU1OAkEQhTtGI4jewMUs3Qx29c8MvTHhR8WEQGJw3WmaGhgC09gNJOy8glfxIB7Ck9gIG1eVvHp5qfoeIbdAm0AZ3BsbmosVTu0cV01mKc0pOyN1kIymokXFOalTyljKMsZr5CqEBaWUA-OXpMYzqpQAqJNhrwzW7dDvE1ck318_H59t7zFsyirtlCbgNGGyO0yHnVE_7aEvd1GR0dUfs3byihbXG-eT9sxVZdiEa3JRmGXAm9NskLenx3G3nw5Gzy_d9iA1wBSkOQpjC5jmLcUzxY2Jh4HMRS5Qosx4y6BUBWUym0yKiUA1zS2oQlgEq0BkvEEejrnr7eTAAKuNN0u99uXK-L12ptT_N1U51zO300oCiBbEgLtTgHfv2_ivXkUQuFyaCt02aJaD4AryiKxB6NEaieuF2_oqfqaB6kMN-k881aBPNfBfIM1-Mw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2714391700</pqid></control><display><type>article</type><title>Discovery of β‑Arrestin-Biased 25CN-NBOH-Derived 5‑HT2A Receptor Agonists</title><source>ACS Publications</source><creator>Poulie, Christian B. M. ; Pottie, Eline ; Simon, Icaro A. ; Harpsøe, Kasper ; D’Andrea, Laura ; Komarov, Igor V. ; Gloriam, David E. ; Jensen, Anders A. ; Stove, Christophe P. ; Kristensen, Jesper L.</creator><creatorcontrib>Poulie, Christian B. M. ; Pottie, Eline ; Simon, Icaro A. ; Harpsøe, Kasper ; D’Andrea, Laura ; Komarov, Igor V. ; Gloriam, David E. ; Jensen, Anders A. ; Stove, Christophe P. ; Kristensen, Jesper L.</creatorcontrib><description>The serotonin 2A receptor (5-HT2AR) is the mediator of the psychedelic effects of serotonergic psychedelics, which have shown promising results in clinical studies for several neuropsychiatric indications. The 5-HT2AR is able to signal through the Gαq and β-arrestin effector proteins, but it is currently not known how the different signaling pathways contribute to the therapeutic effects mediated by serotonergic psychedelics. In the present work, we have evaluated the subtype-selective 5-HT2AR agonist 25CN-NBOH and a series of close analogues for biased signaling at this receptor. These ligands were designed to evaluate the role of interactions with Ser1593×36. The lack of interaction between this hydroxyl moiety and Ser1593×36 resulted in detrimental effects on potency and efficacy in both βarr2 and miniGαq recruitment assays. Remarkably, Gαq-mediated signaling was considerably more affected. This led to the development of the first efficacious βarr2-biased 5-HT2AR agonists 4a–b and 6e–f, βarr2 preferring, relative to lysergic acid diethylamide (LSD).</description><identifier>ISSN: 0022-2623</identifier><identifier>ISSN: 1520-4804</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.2c00702</identifier><identifier>PMID: 36099411</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Journal of medicinal chemistry, 2022-09, Vol.65 (18), p.12031-12043</ispartof><rights>2022 The Authors. Published by American Chemical Society</rights><rights>2022 The Authors. Published by American Chemical Society 2022 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-9326-9644 ; 0000-0001-7126-348X ; 0000-0002-4299-7561 ; 0000-0003-4550-4248 ; 0000-0003-2662-9803 ; 0000-0002-5613-1267 ; 0000-0002-7908-9145</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00702$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00702$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,778,782,883,27063,27911,27912,56725,56775</link.rule.ids></links><search><creatorcontrib>Poulie, Christian B. M.</creatorcontrib><creatorcontrib>Pottie, Eline</creatorcontrib><creatorcontrib>Simon, Icaro A.</creatorcontrib><creatorcontrib>Harpsøe, Kasper</creatorcontrib><creatorcontrib>D’Andrea, Laura</creatorcontrib><creatorcontrib>Komarov, Igor V.</creatorcontrib><creatorcontrib>Gloriam, David E.</creatorcontrib><creatorcontrib>Jensen, Anders A.</creatorcontrib><creatorcontrib>Stove, Christophe P.</creatorcontrib><creatorcontrib>Kristensen, Jesper L.</creatorcontrib><title>Discovery of β‑Arrestin-Biased 25CN-NBOH-Derived 5‑HT2A Receptor Agonists</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The serotonin 2A receptor (5-HT2AR) is the mediator of the psychedelic effects of serotonergic psychedelics, which have shown promising results in clinical studies for several neuropsychiatric indications. The 5-HT2AR is able to signal through the Gαq and β-arrestin effector proteins, but it is currently not known how the different signaling pathways contribute to the therapeutic effects mediated by serotonergic psychedelics. In the present work, we have evaluated the subtype-selective 5-HT2AR agonist 25CN-NBOH and a series of close analogues for biased signaling at this receptor. These ligands were designed to evaluate the role of interactions with Ser1593×36. The lack of interaction between this hydroxyl moiety and Ser1593×36 resulted in detrimental effects on potency and efficacy in both βarr2 and miniGαq recruitment assays. Remarkably, Gαq-mediated signaling was considerably more affected. This led to the development of the first efficacious βarr2-biased 5-HT2AR agonists 4a–b and 6e–f, βarr2 preferring, relative to lysergic acid diethylamide (LSD).</description><issn>0022-2623</issn><issn>1520-4804</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkU1OAkEQhTtGI4jewMUs3Qx29c8MvTHhR8WEQGJw3WmaGhgC09gNJOy8glfxIB7Ck9gIG1eVvHp5qfoeIbdAm0AZ3BsbmosVTu0cV01mKc0pOyN1kIymokXFOalTyljKMsZr5CqEBaWUA-OXpMYzqpQAqJNhrwzW7dDvE1ck318_H59t7zFsyirtlCbgNGGyO0yHnVE_7aEvd1GR0dUfs3byihbXG-eT9sxVZdiEa3JRmGXAm9NskLenx3G3nw5Gzy_d9iA1wBSkOQpjC5jmLcUzxY2Jh4HMRS5Qosx4y6BUBWUym0yKiUA1zS2oQlgEq0BkvEEejrnr7eTAAKuNN0u99uXK-L12ptT_N1U51zO300oCiBbEgLtTgHfv2_ivXkUQuFyaCt02aJaD4AryiKxB6NEaieuF2_oqfqaB6kMN-k881aBPNfBfIM1-Mw</recordid><startdate>20220922</startdate><enddate>20220922</enddate><creator>Poulie, Christian B. M.</creator><creator>Pottie, Eline</creator><creator>Simon, Icaro A.</creator><creator>Harpsøe, Kasper</creator><creator>D’Andrea, Laura</creator><creator>Komarov, Igor V.</creator><creator>Gloriam, David E.</creator><creator>Jensen, Anders A.</creator><creator>Stove, Christophe P.</creator><creator>Kristensen, Jesper L.</creator><general>American Chemical Society</general><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9326-9644</orcidid><orcidid>https://orcid.org/0000-0001-7126-348X</orcidid><orcidid>https://orcid.org/0000-0002-4299-7561</orcidid><orcidid>https://orcid.org/0000-0003-4550-4248</orcidid><orcidid>https://orcid.org/0000-0003-2662-9803</orcidid><orcidid>https://orcid.org/0000-0002-5613-1267</orcidid><orcidid>https://orcid.org/0000-0002-7908-9145</orcidid></search><sort><creationdate>20220922</creationdate><title>Discovery of β‑Arrestin-Biased 25CN-NBOH-Derived 5‑HT2A Receptor Agonists</title><author>Poulie, Christian B. M. ; Pottie, Eline ; Simon, Icaro A. ; Harpsøe, Kasper ; D’Andrea, Laura ; Komarov, Igor V. ; Gloriam, David E. ; Jensen, Anders A. ; Stove, Christophe P. ; Kristensen, Jesper L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a1291-7e4acf1d7893693aa031157474e5e5638ae59f0256bbfb4e9d7c19f4ce1c91463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poulie, Christian B. M.</creatorcontrib><creatorcontrib>Pottie, Eline</creatorcontrib><creatorcontrib>Simon, Icaro A.</creatorcontrib><creatorcontrib>Harpsøe, Kasper</creatorcontrib><creatorcontrib>D’Andrea, Laura</creatorcontrib><creatorcontrib>Komarov, Igor V.</creatorcontrib><creatorcontrib>Gloriam, David E.</creatorcontrib><creatorcontrib>Jensen, Anders A.</creatorcontrib><creatorcontrib>Stove, Christophe P.</creatorcontrib><creatorcontrib>Kristensen, Jesper L.</creatorcontrib><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poulie, Christian B. M.</au><au>Pottie, Eline</au><au>Simon, Icaro A.</au><au>Harpsøe, Kasper</au><au>D’Andrea, Laura</au><au>Komarov, Igor V.</au><au>Gloriam, David E.</au><au>Jensen, Anders A.</au><au>Stove, Christophe P.</au><au>Kristensen, Jesper L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of β‑Arrestin-Biased 25CN-NBOH-Derived 5‑HT2A Receptor Agonists</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2022-09-22</date><risdate>2022</risdate><volume>65</volume><issue>18</issue><spage>12031</spage><epage>12043</epage><pages>12031-12043</pages><issn>0022-2623</issn><issn>1520-4804</issn><eissn>1520-4804</eissn><abstract>The serotonin 2A receptor (5-HT2AR) is the mediator of the psychedelic effects of serotonergic psychedelics, which have shown promising results in clinical studies for several neuropsychiatric indications. The 5-HT2AR is able to signal through the Gαq and β-arrestin effector proteins, but it is currently not known how the different signaling pathways contribute to the therapeutic effects mediated by serotonergic psychedelics. In the present work, we have evaluated the subtype-selective 5-HT2AR agonist 25CN-NBOH and a series of close analogues for biased signaling at this receptor. These ligands were designed to evaluate the role of interactions with Ser1593×36. The lack of interaction between this hydroxyl moiety and Ser1593×36 resulted in detrimental effects on potency and efficacy in both βarr2 and miniGαq recruitment assays. Remarkably, Gαq-mediated signaling was considerably more affected. This led to the development of the first efficacious βarr2-biased 5-HT2AR agonists 4a–b and 6e–f, βarr2 preferring, relative to lysergic acid diethylamide (LSD).</abstract><pub>American Chemical Society</pub><pmid>36099411</pmid><doi>10.1021/acs.jmedchem.2c00702</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-9326-9644</orcidid><orcidid>https://orcid.org/0000-0001-7126-348X</orcidid><orcidid>https://orcid.org/0000-0002-4299-7561</orcidid><orcidid>https://orcid.org/0000-0003-4550-4248</orcidid><orcidid>https://orcid.org/0000-0003-2662-9803</orcidid><orcidid>https://orcid.org/0000-0002-5613-1267</orcidid><orcidid>https://orcid.org/0000-0002-7908-9145</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2022-09, Vol.65 (18), p.12031-12043
issn 0022-2623
1520-4804
1520-4804
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9511481
source ACS Publications
title Discovery of β‑Arrestin-Biased 25CN-NBOH-Derived 5‑HT2A Receptor Agonists
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T22%3A22%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20%CE%B2%E2%80%91Arrestin-Biased%2025CN-NBOH-Derived%205%E2%80%91HT2A%20Receptor%20Agonists&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Poulie,%20Christian%20B.%20M.&rft.date=2022-09-22&rft.volume=65&rft.issue=18&rft.spage=12031&rft.epage=12043&rft.pages=12031-12043&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.2c00702&rft_dat=%3Cproquest_pubme%3E2714391700%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2714391700&rft_id=info:pmid/36099411&rfr_iscdi=true